SynthesisPloS one2019
Personalized breast cancer screening strategies: A systematic review and quality assessment.
Synthesis in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- [Cancer prevention recommendations: Update 2024].Atencion primaria · 2024Guideline
- Understanding the contribution of lifestyle in breast cancer risk prediction: a systematic review of models applicable to Europe.BMC cancer · 2023Pooled it
- Cost effectiveness of breast cancer screening and prevention: a systematic review with a focus on risk-adapted strategies.The European journal of health economics : HEPAC : health economics in prevention and care · 2021Pooled it
- Cost-effectiveness of organised versus opportunistic mammography breast cancer screening in low-resourced country.BMJ open · 2026Article
- WDCN: a comprehensive neural network based approach for estimating breast cancer risk.Briefings in bioinformatics · 2026Article
- Polygenic risk scores in cancer.Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V · 2026Article
- Article
- Personalized screening based on risk and density: prevalence data from the RIBBS study.La Radiologia medica · 2025Observational
- Women's preferences for testing to predict breast cancer risk - a discrete choice experiment.Journal of translational medicine · 2025Article
- Optimizing breast cancer screening strategies for women with different BMI levels in Ghana: A simulation-based study on BMI-dependent tumor growth model.PLOS global public health · 2025Article
- The risk-based breast screening (RIBBS) study protocol: a personalized screening model for young women.La Radiologia medica · 2024Article
- Article
- Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel.Journal of medical genetics · 2023Article
- Breast density analysis of digital breast tomosynthesis.Scientific reports · 2023Article
- Personalized Breast Cancer Screening: A Risk Prediction Model Based on Women Attending BreastScreen Norway.Cancers · 2023Article
- Breast cancer risk assessment and risk distribution in 3,491 Slovenian women invited for screening at the age of 50; a population-based cross-sectional study.Radiology and oncology · 2023Article
- Influence of mammographic density and compressed breast thickness on true mammographic sensitivity: a cohort study.Scientific reports · 2023Article
- Canadian Healthcare Professionals' Views and Attitudes toward Risk-Stratified Breast Cancer Screening.Journal of personalized medicine · 2023Article
- Will Absolute Risk Estimation for Time to Next Screen Work for an Asian Mammography Screening Population?Cancers · 2023Article
- Breast Density Analysis Using Digital Breast Tomosynthesis.bioRxiv : the preprint server for biology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe effectiveness of breast cancer screening is still under debate. Our objective was to systematically review studies assessing personalized breast cancer screening strategies based on women's individual risk and to conduct a risk of bias assessment.
methodsWe followed the standard methods of The Cochrane Collaboration and PRISMA declaration and searched the MEDLINE, EMBASE and Clinical Trials databases for studies published in English. The quality of the studies was assessed using the ISPOR-AMCP-NPC Questionnaire and The Cochrane Risk of Bias Tool. Two independent reviewers screened full texts and evaluated the risk of bias.
resultsOut of the 1533 initially retrieved citations, we included 13 studies. Three studies were randomized controlled trials, while nine were mathematical modeling studies, and one was an observational pilot study. The trials are in the recruitment phase and have not yet reported their results. All three trials used breast density and age to define risk groups, and two of them included family history, previous biopsies, and genetic information. Among the mathematical modeling studies, the main risk factors used to define risk groups were breast density, age, family history, and previous biopsies. Six studies used genetic information to define risk groups. The most common outcome measures were the gain in quality-adjusted life years (QALY), absolute costs, and incremental cost-effectiveness ratio (ICER), while the main outcome in the observational study was the detection rate. In all models, personalized screening strategies were shown to be effective. The randomized trials were of good quality. The modeling studies showed moderate risk of bias but there was wide variability across studies. The observational study showed a low risk of bias but its utility was moderate due to its pilot design and its relatively small scale.
conclusionsThere is some evidence of the effectiveness of screening personalization in terms of QUALYs and ICER from the modeling studies and the observational study. However, evidence is lacking on feasibility and acceptance by the target population. REVIEW REGISTRATION: PROSPERO: CRD42018110483.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.